Novartis Vaccines & Diagnostics, Inc. Signs Agreement With ProMetic BioSciences, Inc. To Develop An Affinity Ligand For Vaccine Purification

MONTREAL, CANADA -- (MARKET WIRE) -- December 04, 2006 -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that its UK subsidiary ProMetic Biosciences Ltd ("PBL") has entered into an agreement with Novartis Vaccines and Diagnostics GmbH & Co.K.G (NYSE: NVS) ("Novartis"), to develop a synthetic-ligand affinity adsorbent for the purification of a recombinant protein vaccine. Under the terms of the agreement PBL will receive funding from Novartis to screen its Chemical Combinatorial Libraries® for ligands suitable for the processscale purification of a new vaccine product developed by Novartis and currently undergoing clinical trials. The work is to be conducted at PBL's research laboratories located at the Cambridge Science Park, UK.

Back to news